SEARCH

Current Edition

Barron

GSK loses R&D chief Barron to high-powered startup amid investor pressure

Hal Barron, GlaxoSmithKline’s top scientist and architect of the company’s plans to revitalize its drug research, will step down from his role later this year …

Continue Reading →